Howard Abrams

Howard Abrams

Auto-generated profile, based on publicly available information

Howard Abrams

University Health Network

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 1986 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
ADAllan S. Detsky
Allan S. Detsky
HAHoward B. Abrams
Howard B. Abrams
JMJohn R. McLaughlin
John R. McLaughlin
DDDaniel J. Drucker
Daniel J. Drucker
ZSZion Sasson
Zion Sasson
JHJoseph R. Hilliard
Joseph R. Hilliard

1 March 2004 in Journal of General Internal Medicine
Verified
Journal Article
Closed access
PDF file
AJAva John-Baptiste
Ava John-Baptiste
GNGary Naglie
Gary Naglie
GTGeorge A. Tomlinson
George A. Tomlinson
SAShabbir Alibhai
Shabbir Alibhai
EEEdward Etchells
Edward Etchells
MKMurray Krahn
Murray Krahn

1 October 2015 in The Lancet Global Health
Verified
Journal Article
Open access
NLNathan C Lo
Nathan C Lo
IBIsaac I Bogoch
Isaac I Bogoch
BBBrian G Blackburn
Brian G Blackburn
GRGiovanna Raso
Giovanna Raso
ENEliézer K N'GOran
Eliézer K N'GOran
JAJason R Andrews
Jason R Andrews
More than 1·5 billion people are affected by schistosomiasis or soil-transmitted helminthiasis. WHO's recommendations for mass drug administration (MDA) against these parasitic infections emphasise treatment of school-aged children, using separate treatment guidelines for these two helminthiases groups. We aimed to evaluate the cost-effectiveness of expanding integrated MDA to the entire community in four settings in Côte d'Ivoire. We extended previously published, dynamic, age-structured models of helminthiases transmission to simulate costs and disability averted with integrated MDA (of praziquantel and albendazole) for schistosomiasis and soil-transmitted helminthiasis. We calibrated the model to data for prevalence and intensity of species-specific helminth infection from surveys undertaken in four communities in Côte d'Ivoire between March, 1997, and September, 2010. We simulated a 15-year treatment programme with 75% coverage in only school-aged children; school-aged children and preschool-aged children; adults; and the entire community. Treatment costs were estimated at US$0·74 for school-aged children and $1·74 for preschool-aged children and adults. The incremental cost-effectiveness ratio (ICER) was calculated in 2014 US dollars per disability-adjusted life-year (DALY) averted. Expanded community-wide treatment was highly cost effective compared with treatment of only school-aged children (ICER $167 per DALY averted) and WHO guidelines (ICER $127 per DALY averted), and remained highly cost effective even if treatment costs for preschool-aged children and adults were ten times greater than those for school-aged children. Community-wide treatment remained highly cost effective even when elimination of helminth infections was not achieved. These findings were robust across the four diverse communities in Côte d'Ivoire, only one of which would have received annual MDA for both schistosomiasis and soil-transmitted helminthiasis under the latest WHO guidelines. Treatment every 6 months was also highly cost effective in three out of four communities. Integrated, community-wide MDA programmes for schistosomiasis and soil-transmitted helminthiasis can be highly cost effective, even in communities with low disease burden in any helminth group. These results support an urgent need to re-evaluate current global guidelines for helminthiases control programmes to include community-wide treatment, increased treatment frequency, and consideration for lowered prevalence thresholds for integrated treatment. Stanford University Medical Scholars Programme, Mount Sinai Hospital-University Health Network AMO Innovation Fund.

1 November 2010 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
PDF file
RWRobert C. Wu
Robert C. Wu
DMDante Morra
Dante Morra
SQSherman Quan
Sherman Quan
SLSannie Lai
Sannie Lai
SZSamira Zanjani
Samira Zanjani
PRPeter G. Rossos
Peter G. Rossos

1 October 2014 in JAMA
Verified
Journal Article
Open access
PDF file
IDIrfan A. Dhalla
Irfan A. Dhalla
TOTara O’bRien
Tara O’bRien
DMDante Morra
Dante Morra
KTKevin E. Thorpe
Kevin E. Thorpe
BWBrian M. Wong
Brian M. Wong
ALAndreas Laupacis
Andreas Laupacis
Quiz Ref ID Readmissions after hospital discharge are common,1 costly, and believed by many to be an indicator of suboptimal health care.2 In the United States, hospitals are now financially penalized if their readmission rates for Medicare patients are deemed excessive.3 These penalties are set to increase to up to 3% of a hospital’s Medicare reimbursement in 2015. This “pay-for-performance” program has been implemented despite limited evidence supporting the hypothesis that hospitals can implement initiatives that will successfully and consistently reduce readmissions.

1 November 1986 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
ADAllan S. Detsky
Allan S. Detsky
HAHoward B. Abrams
Howard B. Abrams
NFNicholas Forbath
Nicholas Forbath
JSJ. Gerald Scott
J. Gerald Scott
JHJoseph R. Hilliard
Joseph R. Hilliard
Research from JAMA Internal Medicine — Cardiac Assessment for Patients Undergoing Noncardiac Surgery A Multifactorial Clinical Risk Index